Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Renard E, Dancer P-A, Portal C, Denat F, Prignon A, Goncalves V |
Journal | JOURNAL OF MEDICINAL CHEMISTRY |
Volume | 63 |
Pagination | 2426-2433 |
Date Published | MAR 12 |
Type of Article | Article |
ISSN | 0022-2623 |
Résumé | Neurotensin receptor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas. It makes it an attractive target for the development of pancreatic cancer imaging agents. In this study, we sought to develop a bimodal positron emission tomography (PET)/fluorescent imaging agent capable of specifically targeting these receptors. Starting from the structure of a known NTSR1 agonist, a series of tracers were synthesized, radiometalated with gallium-68, and evaluated in vitro and in vivo, in mice bearing an AsPC-1 xenograft. PET imaging allowed us to identify the compound [Ga-68]Ga-NODAGA-Lys(Cy5**)-AEEAc-[Me-Arg(8),Tle(12)]-NT(7-13) as the one with the most promising biodistribution profile, characterized by high tumor uptake (2.56 +/- 0.97%ID/g, 1 h post-injection) and rapid elimination from nontargeted organs, through urinary excretion. Fluorescence imaging gave similar results. On this basis, fluorescence-guided resection of tumor masses was successfully carried out on a preclinical model. |
DOI | 10.1021/acs.jmedchem.9b01407 |